Compare Harley-Davidson Inc (HOG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Illumina, Inc. — how do they compare? Harley-Davidson Inc trades at $27.89 (market cap $2.93B), while Illumina, Inc. trades at $184.68 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 9.5× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.64% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| HOG | ILMN | |
|---|---|---|
Market Cap | $2.93B | $27.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $194.33 |
52-Week Low | $17.19 | $91.00 |
Enterprise Value | $3.32B | $29.33B |
Dividend Yield | 2.64% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
